Global Kras Inhibitors Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Global Kras Inhibitors Market is segmented By Drug Type (Small Molecule Inhibitors, Monoclonal Antibodies, Combination Therapies), By Indication (Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Cancer), By Route of Administration (Oral, Intravenous, Others), By Cancer Type (Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others), By End User (Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned segments.
Global Kras Inhibitors Market Size
Market Size in USD
CAGR4.98%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 4.98% |
| Market Concentration | High |
| Major Players | Amgen, Boehringer Ingelheim, Mirati Therapeutics, Novartis, BridgeBio Pharma |
please let us know !
Global Kras Inhibitors Market Analysis
The Global Kras Inhibitors Market is estimated to be valued at USD 104.5 Mn in 2024 and is expected to reach USD 146.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.98% from 2024 to 2031. The market has seen steady growth in recent years driven by increasing demand for targeted cancer therapies and the expanding focus on developing novel therapeutic drugs for treating various cancers.
The Kras inhibitors market is expected to witness positive growth over the forecast period supported by ongoing clinical trials evaluating the efficacy of different Kras inhibitors either as monotherapy or in combination with other targeted drugs. Major pharmaceutical companies have shown increased investments in cancer drug research and development which will accelerate the market trends.